Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide phase 1 study of healthy adults

AIDS Research and Human Retroviruses

Volumn 27, Issue 5, 2011, Pages 557-567

  Nicholson, Ouzama ^a,b   Dicandilo, Fay ^a,b   Kublin, James ^c   Sun, Xiao ^a,b   Quirk, Erin ^a,b   Miller, Michelle ^a,b   Gray, Glenda ^d   Pape, Jean ^e   Robertson, Michael N ^a,b   Mehrotra, Devan V ^a,b   Self, Steven ^c   Turner, Katherine ^c   Sanchez, Jorge ^f,g   Pitisuttithum, Punnee ^h   Duerr, Ann ^c,i   Dubey, Sheri ^a,b   Kierstead, Lisa ^a,b   Casimiro, Danilo ^a,b   Hammer, Scott M ^j  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^g Investigaciones Medicas en Salud   (Peru)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j Howard Hughes Medical Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASIA; BACKACHE; CENTRAL AMERICA; CLADISTICS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORTH AMERICA; NOSE CONGESTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SEROPREVALENCE; SORE THROAT; SOUTH AFRICA; SOUTH AMERICA; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

EID: 79955774295     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0151     Document Type: Article

References (78)

1. UNAIDS The Joint United Nation Programme on HIV/ AIDS: 2008 report on the global AIDS epidemic: Executive summary, 2008.
2. Bennett DE: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006;19:607-614.
3. Laurent C, Meilo H, Guiard-Schmid J-B, et al.: Antiretroviral therapy in public and private routine health care clinics in Cameroon: Lessons from the Douala Antiretroviral (DARVIR) Initiative. Clin Infect Dis 2005;41:108-111. (Pubitemid 40863752)
4. Muula AS, Chipeta J, Siziya S, Rudatsikira E, Mataya RH, and Kataika E: Human resources requirements for highly active antiretroviral therapy scale-up in Malawi. BMC Health Serv Res 2007;7:208.
5. Shekelle P, Maglione M, Geotz MB, Wagner G, Wang Z, Hilton L, et al.: Antiretroviral (ARV) drug resistance in the developing world. Evidence Report/Technology Assessment No. 156. (Prepared by Southern California Evidencebased Practice Center, Contract No. 290-02-0003.) AHRQ Publication No. 07-E014. Agency for Healthcare Research and Quality, Rockville, MD, 2007.
6. Galluzzo CM, Germinario EAP, Bassani L, et al.: Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda [letter to the editor]. AIDS Res Hum Retroviruses 2007;23:1449-1451.
7. Marconi VC, Sunpath H, Lu Z, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597. (Pubitemid 351706742)
8. Martinson NA, Morris L, Gray G, et al.: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153. (Pubitemid 46292216)
9. Ndembi N, Abraha A, Pilch H, et al.: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008;46:177-184.
10. Toni TD, Masquelier B, Minga A, et al.: HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cô te d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 2007;23:1155-1160. (Pubitemid 47571940)
11. Lyles CM, Kay LS, Crepaz N, et al.: Best-evidence interventions: Findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. Am J Public Health 2007;97:133-143. (Pubitemid 46067695)
12. Anderson KG, Beutel AM, and Maughan-Brown B: HIV risk perceptions and first sexual intercourse among youth in Cape Town, South Africa. Int Fam Plan Perspect 2007;33:98-105. (Pubitemid 350020557)
13. Dancy BL, Kaponda CPN, Kachingwe SI, and Norr KF: Risky sexual behaviors of adolescents in rural Malawi: Evidence from focus groups. J Natl Black Nurses Assoc 2006;17:22-28.
14. Holtgrave D: Evidence-based efforts to prevent HIV infection: An overview of current status and future challenges. Clin Infect Dis 2007;45:S293-S299. (Pubitemid 351417232)
15. Holtgrave DR and Curran JW: What works, and what remains to be done, in HIV prevention in the United States. Annu Rev Public Health 2006;27:261-275.
16. Ickovics JR: "Bundling" HIV prevention: Integrating services to promote synergistic gain. Prev Med 2008;46:222-225. (Pubitemid 351308148)
17. Levy NC, Miksad RA, and Fein OT: From treatment to prevention: The interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. J Urban Health 2005;82:498-509. (Pubitemid 41191568)
18. Lurie M, Pronyk P, de Moor E, et al.: Sexual behavior and reproductive health among HIV-infected patients in urban and rural South Africa. J Acquir Immune Defic Syndr 2008;47:484-493. (Pubitemid 351366965)
19. Maganja RK, Maman S, Groves A, and Mbwambo JK: Skinning the goat and pulling the load: Transactional sex among youth in Dar es Salaam, Tanzania. AIDS Care 2007; 19:974-981. (Pubitemid 47402887)
20. Nkosana J and Rosenthal D: The dynamics of intergeneraltional sexual relationships: The experience of schoolgirls in Botswana. Sex Health 2007;4:181-187. (Pubitemid 47339636)
21. Nagelkerke NJD, Moses S, de Vlas SJ, and Bailey RC: Modelling the public health impact of male circumcision for HIV prevention in high prevalence area in Africa. BMC Infect Dis 2007;7:16.
22. Quinn TC: Circumcision and HIV transmission. Curr Opin Infect Dis 2007;20:33-38. (Pubitemid 46052124)
23. Sahasrabuddhe VV and Vermund SH: The future of HIV prevention: Control of sexually transmitted infections and circumcision interventions. Infect Dis Clin North Am 2007;21:241-257. (Pubitemid 46719805)
24. Williams BG, Lloyd-Smith JO, Gouws E, et al.: The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med 2006;3:1032-1040. (Pubitemid 44125989)
25. Bailey RC, Moses S, Parker CB, et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007;369:643-656. (Pubitemid 46281312)
26. Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 2007;369:657-666.
27. Karim Q, Karim S, Frohlich J, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
28. Amirfar S, Hollenberg JP, and Abdool Karim SS: Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006;43:219-225. (Pubitemid 44454817)
29. Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, and Paltiel AD: Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example. J Acquir Immune Defic Syndr 2007;46:78-90. (Pubitemid 47507437)
30. Blower SM, Bodine EN, and Grovit-Ferbas K: Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: The problem of subtypes. Curr Drug Targets 2005;5:179-192. (Pubitemid 40974797)
31. Pantaleo G and Koup RA: Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004;10:806-810. (Pubitemid 39070851)
32. Draenert R, Le Gall S, Pfafferott KJ, et al.: Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199:905-915. (Pubitemid 38481082)
33. Yokomaku Y, Miura H, Tomiyama H, et al.: Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 Infection. J Virol 2004;78:1324-1332. (Pubitemid 38095842)
34. Allen TM, Altfeld M, Geer SC, et al.: Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005;79:13239-13249. (Pubitemid 41508139)
35. Ammaranond P, Zaunders J, Satchell C, Van Bockel D, Cooper DA, and Kelleher AD: A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1. AIDS Res Hum Retroviruses 2005;21:395-397. (Pubitemid 40800455)
36. Pillay T, Zhang H-T, Drijfhout JW, et al.: Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection. J Virol 2005;79: 12100-12105. (Pubitemid 41279328)
37. Á vila-Ríos S, Reyes-Terán G, and Espinosa E: Cornering HIV: Taking advantage of interactions between selective pressures. Med Hypotheses 2007;69:422-431. (Pubitemid 46818696)
38. Seaman MS, Xu L, Beaudry K, et al.: Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005;79:2956-2963. (Pubitemid 40270574)
39. Thomson MM, Pérez-Á varez L, Ná jera R: Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2:461-471. (Pubitemid 34826851)
40. van der Groen G, Nyambi PN, Beirnaert E, et al.: Genetic variation of HIV type 1: Relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses 1998; 14:S-211-S-221. (Pubitemid 28513476)
41. The rgp120 HIV Vaccine Study Group: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
42. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671. (Pubitemid 44901996)
43. Ferrari G, Humphrey W, McElrath MJ, et al.: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401. (Pubitemid 27087862)
44. Buseyne F, Chaix ML, Fleury B, et al.: Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology 1998;250:316-324. (Pubitemid 28489631)
45. Ferrari G, Kostyu DD, Cox J, et al.: Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000;16:1433-1443.
46. Fukada K, Tomiyama H, Wasi C, et al.: Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS 2002; 16:701-711. (Pubitemid 34274460)
47. Lynch JA, deSouza M, Robb MD, et al.: Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998;178:1040-1046. (Pubitemid 28452196)
48. Wilson SE, Pedersen SL, Kunich JC, et al.: Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 1998;14:925-937. (Pubitemid 28337481)
49. Coplan PM, Gupta SB, Dubey SA, et al.: Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005;191:1427-1434. (Pubitemid 40563353)
50. Barouch DH, Kunstman J, Glowczwskie J, et al.: Viral escape from dominant simian immunodeficiency virus epitopespecific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003;77:7367-7375. (Pubitemid 36734505)
51. Barouch DH, Santra S, Kuroda MJ, et al.: Reduction of simian- human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001;75:5151-5158. (Pubitemid 32448537)
52. Belshe RB, Stevens C, Gorse GJ, et al.: Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343-1352. (Pubitemid 32337116)
53. Evans TG, Keefer MC, Weinhold KJ, et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290-298. (Pubitemid 30256308)
54. Fang Z-Y, Kuli-Zade I, and Spearman P: Efficient human immunodeficiency virus (HIV)-1 gag-env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis 1999;180:1122-1132. (Pubitemid 30070195)
55. Fleury B, Janvier G, Pialoux G, et al.: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174: 734-738. (Pubitemid 26325888)
56. Goepfert PA, Horton H, McElrath MJ, et al.: High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005;192: 1249-1259. (Pubitemid 41368426)
57. Gupta K, Hudgens M, Corey L, et al.: Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-261. (Pubitemid 34208533)
58. Hanke T, Samuel RV, Blanchard TJ, et al.: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vacccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532. (Pubitemid 29383236)
59. Hel Z, Nacsa J, Tryniszewska E, et al.: Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002;169:4778-4787. (Pubitemid 35217140)
60. Hel Z, Tsai WP, Thornton A., et al.: Potentiation of simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 2001;167:7180-7191. (Pubitemid 33144216)
61. Shen L, Chen ZW, Miller MD, et al.: Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-443. (Pubitemid 21916982)
62. Catanzaro AT, Koup RA, Roederer M, et al.: Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194:1638-1649. (Pubitemid 44901994)
63. Casimiro DR, Wang F, Schleif WA, et al.: Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing gag. J Virol 2005;79: 15547-15555. (Pubitemid 43032336)
64. Casimiro DR, Chen L, Fu T-M, et al.: Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-6313. (Pubitemid 36588400)
65. Shiver JW, Fu T-M, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity [letter]. Nature 2002;415:331-335. (Pubitemid 34087555)
66. Santra S, Seaman MS, Xu L, et al.: Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005;79:6516-6522. (Pubitemid 40617255)
67. Robertson M, Mehrotra D, Fitzgerald D, et al.: Efficacy results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine. 15th Conference on Retroviruses and Opportunistic Infections 2008. Abstract 88LB.
68. Buchbinder SP, Mehrotra DV, Duerr A, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 2008;372:1881-1893.
69. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
70. Wu X, Yang ZY, Liang Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861.
71. Harro CD, Robertson MN, Lally MA, et al.: Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009;25:1-12.
72. Dubey S, Clair J, Fu T-M, et al.: Detection of HIV vaccineinduced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007;45:20-27. (Pubitemid 46684439)
73. Kierstead LS, Dubey S, Meyer B, et al.: Enhanced rates and magnitude of immune responses detected against an HIV vaccine: Effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 2007;23:86-92. (Pubitemid 46214176)
74. Aste-Amézaga M, Bett AJ, Wang F, et al.: Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies in the design of adenovector vaccines. Hum Gene Ther 2004;15:293-304. (Pubitemid 38365918)
75. Miettinen O and Nurminen M: Comparative analysis of two rates. Stat Med 1985;4:213-226. (Pubitemid 15055349)
76. Mehrotra DV and Heyse JF: Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res 2004;13:227-238. (Pubitemid 38744605)
77. Kaslow RA, Carrington M, Apple R, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2: 405-411. (Pubitemid 26193012)
78. Quirk EK, Mogg R, Brown DD, et al.: HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Clin Infect Dis 2008;47:1593-1599.